Cargando…
Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice
BACKGROUND: Polypharmacy interventions are resource-intensive and should be targeted to those at risk of negative health outcomes. Our aim was to develop and internally validate prognostic models to predict health-related quality of life (HRQoL) and the combined outcome of falls, hospitalisation, in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583076/ https://www.ncbi.nlm.nih.gov/pubmed/33093036 http://dx.doi.org/10.1136/bmjopen-2020-039747 |
_version_ | 1783599336903409664 |
---|---|
author | Müller, Beate S Uhlmann, Lorenz Ihle, Peter Stock, Christian von Buedingen, Fiona Beyer, Martin Gerlach, Ferdinand M Perera, Rafael Valderas, Jose Maria Glasziou, Paul van den Akker, Marjan Muth, Christiane |
author_facet | Müller, Beate S Uhlmann, Lorenz Ihle, Peter Stock, Christian von Buedingen, Fiona Beyer, Martin Gerlach, Ferdinand M Perera, Rafael Valderas, Jose Maria Glasziou, Paul van den Akker, Marjan Muth, Christiane |
author_sort | Müller, Beate S |
collection | PubMed |
description | BACKGROUND: Polypharmacy interventions are resource-intensive and should be targeted to those at risk of negative health outcomes. Our aim was to develop and internally validate prognostic models to predict health-related quality of life (HRQoL) and the combined outcome of falls, hospitalisation, institutionalisation and nursing care needs, in older patients with multimorbidity and polypharmacy in general practices. METHODS: Design: two independent data sets, one comprising health insurance claims data (n=592 456), the other data from the PRIoritising MUltimedication in Multimorbidity (PRIMUM) cluster randomised controlled trial (n=502). Population: ≥60 years, ≥5 drugs, ≥3 chronic diseases, excluding dementia. Outcomes: combined outcome of falls, hospitalisation, institutionalisation and nursing care needs (after 6, 9 and 24 months) (claims data); and HRQoL (after 6 and 9 months) (trial data). Predictor variables in both data sets: age, sex, morbidity-related variables (disease count), medication-related variables (European Union-Potentially Inappropriate Medication list (EU-PIM list)) and health service utilisation. Predictor variables exclusively in trial data: additional socio-demographics, morbidity-related variables (Cumulative Illness Rating Scale, depression), Medication Appropriateness Index (MAI), lifestyle, functional status and HRQoL (EuroQol EQ-5D-3L). Analysis: mixed regression models, combined with stepwise variable selection, 10-fold cross validation and sensitivity analyses. RESULTS: Most important predictors of EQ-5D-3L at 6 months in best model (Nagelkerke’s R² 0.507) were depressive symptoms (−2.73 (95% CI: −3.56 to −1.91)), MAI (−0.39 (95% CI: −0.7 to −0.08)), baseline EQ-5D-3L (0.55 (95% CI: 0.47 to 0.64)). Models based on claims data and those predicting long-term outcomes based on both data sets produced low R² values. In claims data-based model with highest explanatory power (R²=0.16), previous falls/fall-related injuries, previous hospitalisations, age, number of involved physicians and disease count were most important predictor variables. CONCLUSIONS: Best trial data-based model predicted HRQoL after 6 months well and included parameters of well-being not found in claims. Performance of claims data-based models and models predicting long-term outcomes was relatively weak. For generalisability, future studies should refit models by considering parameters representing well-being and functional status. |
format | Online Article Text |
id | pubmed-7583076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-75830762020-10-28 Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice Müller, Beate S Uhlmann, Lorenz Ihle, Peter Stock, Christian von Buedingen, Fiona Beyer, Martin Gerlach, Ferdinand M Perera, Rafael Valderas, Jose Maria Glasziou, Paul van den Akker, Marjan Muth, Christiane BMJ Open General practice / Family practice BACKGROUND: Polypharmacy interventions are resource-intensive and should be targeted to those at risk of negative health outcomes. Our aim was to develop and internally validate prognostic models to predict health-related quality of life (HRQoL) and the combined outcome of falls, hospitalisation, institutionalisation and nursing care needs, in older patients with multimorbidity and polypharmacy in general practices. METHODS: Design: two independent data sets, one comprising health insurance claims data (n=592 456), the other data from the PRIoritising MUltimedication in Multimorbidity (PRIMUM) cluster randomised controlled trial (n=502). Population: ≥60 years, ≥5 drugs, ≥3 chronic diseases, excluding dementia. Outcomes: combined outcome of falls, hospitalisation, institutionalisation and nursing care needs (after 6, 9 and 24 months) (claims data); and HRQoL (after 6 and 9 months) (trial data). Predictor variables in both data sets: age, sex, morbidity-related variables (disease count), medication-related variables (European Union-Potentially Inappropriate Medication list (EU-PIM list)) and health service utilisation. Predictor variables exclusively in trial data: additional socio-demographics, morbidity-related variables (Cumulative Illness Rating Scale, depression), Medication Appropriateness Index (MAI), lifestyle, functional status and HRQoL (EuroQol EQ-5D-3L). Analysis: mixed regression models, combined with stepwise variable selection, 10-fold cross validation and sensitivity analyses. RESULTS: Most important predictors of EQ-5D-3L at 6 months in best model (Nagelkerke’s R² 0.507) were depressive symptoms (−2.73 (95% CI: −3.56 to −1.91)), MAI (−0.39 (95% CI: −0.7 to −0.08)), baseline EQ-5D-3L (0.55 (95% CI: 0.47 to 0.64)). Models based on claims data and those predicting long-term outcomes based on both data sets produced low R² values. In claims data-based model with highest explanatory power (R²=0.16), previous falls/fall-related injuries, previous hospitalisations, age, number of involved physicians and disease count were most important predictor variables. CONCLUSIONS: Best trial data-based model predicted HRQoL after 6 months well and included parameters of well-being not found in claims. Performance of claims data-based models and models predicting long-term outcomes was relatively weak. For generalisability, future studies should refit models by considering parameters representing well-being and functional status. BMJ Publishing Group 2020-10-22 /pmc/articles/PMC7583076/ /pubmed/33093036 http://dx.doi.org/10.1136/bmjopen-2020-039747 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | General practice / Family practice Müller, Beate S Uhlmann, Lorenz Ihle, Peter Stock, Christian von Buedingen, Fiona Beyer, Martin Gerlach, Ferdinand M Perera, Rafael Valderas, Jose Maria Glasziou, Paul van den Akker, Marjan Muth, Christiane Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
title | Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
title_full | Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
title_fullStr | Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
title_full_unstemmed | Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
title_short | Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
title_sort | development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice |
topic | General practice / Family practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583076/ https://www.ncbi.nlm.nih.gov/pubmed/33093036 http://dx.doi.org/10.1136/bmjopen-2020-039747 |
work_keys_str_mv | AT mullerbeates developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT uhlmannlorenz developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT ihlepeter developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT stockchristian developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT vonbuedingenfiona developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT beyermartin developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT gerlachferdinandm developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT pererarafael developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT valderasjosemaria developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT glaszioupaul developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT vandenakkermarjan developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice AT muthchristiane developmentandinternalvalidationofprognosticmodelstopredictnegativehealthoutcomesinolderpatientswithmultimorbidityandpolypharmacyingeneralpractice |